dc.contributor.author | Passaro, A | |
dc.contributor.author | Wang, J | |
dc.contributor.author | Wang, Y | |
dc.contributor.author | Lee, S-H | |
dc.contributor.author | Melosky, B | |
dc.contributor.author | Shih, J-Y | |
dc.contributor.author | Wang, J | |
dc.contributor.author | Azuma, K | |
dc.contributor.author | Juan-Vidal, O | |
dc.contributor.author | Cobo, M | |
dc.contributor.author | Felip, E | |
dc.contributor.author | Girard, N | |
dc.contributor.author | Cortot, AB | |
dc.contributor.author | Califano, R | |
dc.contributor.author | Cappuzzo, F | |
dc.contributor.author | Owen, S | |
dc.contributor.author | Popat, S | |
dc.contributor.author | Tan, J-L | |
dc.contributor.author | Salinas, J | |
dc.contributor.author | Tomasini, P | |
dc.contributor.author | Gentzler, RD | |
dc.contributor.author | William, WN | |
dc.contributor.author | Reckamp, KL | |
dc.contributor.author | Takahashi, T | |
dc.contributor.author | Ganguly, S | |
dc.contributor.author | Kowalski, DM | |
dc.contributor.author | Bearz, A | |
dc.contributor.author | MacKean, M | |
dc.contributor.author | Barala, P | |
dc.contributor.author | Bourla, AB | |
dc.contributor.author | Girvin, A | |
dc.contributor.author | Greger, J | |
dc.contributor.author | Millington, D | |
dc.contributor.author | Withelder, M | |
dc.contributor.author | Xie, J | |
dc.contributor.author | Sun, T | |
dc.contributor.author | Shah, S | |
dc.contributor.author | Diorio, B | |
dc.contributor.author | Knoblauch, RE | |
dc.contributor.author | Bauml, JM | |
dc.contributor.author | Campelo, RG | |
dc.contributor.author | Cho, BC | |
dc.contributor.author | MARIPOSA-2 Investigators, | |
dc.coverage.spatial | England | |
dc.date.accessioned | 2024-01-17T13:41:05Z | |
dc.date.available | 2024-01-17T13:41:05Z | |
dc.date.issued | 2023-10-23 | |
dc.identifier | S0923-7534(23)04281-3 | |
dc.identifier.citation | Annals of Oncology, 2023, pp. S0923-7534(23)04281-3 - | |
dc.identifier.issn | 0923-7534 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/6113 | |
dc.identifier.eissn | 1569-8041 | |
dc.identifier.eissn | 1569-8041 | |
dc.identifier.doi | 10.1016/j.annonc.2023.10.117 | |
dc.identifier.doi | 10.1016/j.annonc.2023.10.117 | |
dc.description.abstract | BACKGROUND: Amivantamab plus carboplatin-pemetrexed (chemotherapy) with and without lazertinib demonstrated antitumor activity in patients with refractory epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) in phase I studies. These combinations were evaluated in a global phase III trial. PATIENTS AND METHODS: A total of 657 patients with EGFR-mutated (exon 19 deletions or L858R) locally advanced or metastatic NSCLC after disease progression on osimertinib were randomized 2 : 2 : 1 to receive amivantamab-lazertinib-chemotherapy, chemotherapy, or amivantamab-chemotherapy. The dual primary endpoints were progression-free survival (PFS) of amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy. During the study, hematologic toxicities observed in the amivantamab-lazertinib-chemotherapy arm necessitated a regimen change to start lazertinib after carboplatin completion. RESULTS: All baseline characteristics were well balanced across the three arms, including by history of brain metastases and prior brain radiation. PFS was significantly longer for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy [hazard ratio (HR) for disease progression or death 0.48 and 0.44, respectively; P < 0.001 for both; median of 6.3 and 8.3 versus 4.2 months, respectively]. Consistent PFS results were seen by investigator assessment (HR for disease progression or death 0.41 and 0.38 for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy, respectively; P < 0.001 for both; median of 8.2 and 8.3 versus 4.2 months, respectively). Objective response rate was significantly higher for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (64% and 63% versus 36%, respectively; P < 0.001 for both). Median intracranial PFS was 12.5 and 12.8 versus 8.3 months for amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy versus chemotherapy (HR for intracranial disease progression or death 0.55 and 0.58, respectively). Predominant adverse events (AEs) in the amivantamab-containing regimens were hematologic, EGFR-, and MET-related toxicities. Amivantamab-chemotherapy had lower rates of hematologic AEs than amivantamab-lazertinib-chemotherapy. CONCLUSIONS: Amivantamab-chemotherapy and amivantamab-lazertinib-chemotherapy improved PFS and intracranial PFS versus chemotherapy in a population with limited options after disease progression on osimertinib. Longer follow-up is needed for the modified amivantamab-lazertinib-chemotherapy regimen. | |
dc.format | Print-Electronic | |
dc.format.extent | S0923-7534(23)04281-3 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | ELSEVIER | |
dc.relation.ispartof | Annals of Oncology | |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/4.0/ | |
dc.subject | EGFR-mutated | |
dc.subject | NSCLC | |
dc.subject | amivantamab | |
dc.subject | lazertinib | |
dc.subject | post-osimertinib | |
dc.title | Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-10-12 | |
dc.date.updated | 2024-01-17T13:34:42Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1016/j.annonc.2023.10.117 | |
rioxxterms.licenseref.startdate | 2023-10-23 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/37879444 | |
pubs.organisational-group | ICR | |
pubs.organisational-group | ICR/Primary Group | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology | |
pubs.organisational-group | ICR/Primary Group/ICR Divisions/Clinical Studies/Thoracic Oncology/Thoracic Oncology (hon.) | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1016/j.annonc.2023.10.117 | |
dc.contributor.icrauthor | Popat, Sanjay | |
icr.provenance | Deposited by Mr Arek Surman on 2024-01-17. Deposit type is initial. No. of files: 1. Files: 1-s2.0-S0923753423042813-main.pdf | |